Evoke Pharma, Inc. has completed the production of a commercial scale lot of EVK-001 in accordance with FDA standards for chemistry, manufacturing, and controls (CMC), demonstrating its ability for large scale production of its intranasal formulation of metoclopramide.      Along with previous studies, which have all met proposed specifications, these CMC datasets will be used as part of a NDA following data from Evoke’s Phase III trial for EVK-001 in treating symptoms related to diabetic...